Correlation between p53 mutation and cyclin D1 amplification in head and neck squamous cell carcinoma

European Journal of Cancer Part B: Oral Oncology

Volumn 33, Issue 1, 1997, Pages 42-46

  Mineta, H ^a   Borg, Å ^c   Dictor, M ^b   Wahlberg, P ^c   Wennerberg, J ^c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c NONE

Author keywords

Carcinoma; Cyclin D1; Head and neck neoplasm; p53; Squamous cell

Indexed keywords

CYCLIN D1; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; CYCLINS; EXONS; FEMALE; GENE AMPLIFICATION; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; ONCOGENE PROTEINS; ONCOGENES; POINT MUTATION; POLYMERASE CHAIN REACTION;

EID: 0030907272     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0964-1955(96)00039-5     Document Type: Article

References (37)

1. 1. Somers, K. D., Merrick, M. A., Lopez, M. E., Incognito, I. S., Schechter, G. I. and Casey, G., Frequent p53 mutations in head and neck cancer. Cancer Research, 1992, 52, 5997-6000.
2. 2. Xu, L., Davidson, B. J., Murty, V. V. V. S., et al., TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma lines. International Journal of Cancer, 1994, 59, 383-387.
3. 3. Field, J. K., Pavelic, Z. P., Spandidos, D. A., Stambrook, P. J., Jones, A. S. and Gluckman, J. L., The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Archives of Otolaryngology Head and Neck Surgery, 1993, 119, 1118-1122.
4. 4. Boyle, J., Hakim, J., Koch, W., et al., The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Research, 1993, 53, 4477-4480.
5. 5. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C., p53 mutations in human cancers. Science (Washington DC), 1991, 253, 49-53.
6. 6. Levine, A. J., Momand, J. and Finlay, C. A., The p53 tumour suppressor gene. Nature (London), 1991, 351, 453-456.
7. 7. Harris, C. C. and Hollstein, M., Clinical implications of the p53 tumor-suppressor gene. New England Journal of Medicine, 1993, 329, 1318-1327.
8. 8. Vogelstein, N. and Kinzler, K. W., p53 function and dysfunction. Cell, 1992, 70, 523-526.
9. 9. Montenarh, M., Functional implications of the growth-suppressor/onco-protein p53. International Journal of Oncology, 1992, 1, 37-45.
10. 10. Levine, A. J., Perry, M. E., Chang, A., et al., The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigeneses. British Journal of Cancer, 1994, 69, 409-416.
11. 11. Lammie, G. A. and Peters, G., Chromosome 11q13 abnormalities in human cancer. Cancer Cells, 1991, 3, 413-420.
12. 12. Greenblatt, M. S., Bennett, W. P., Hollstein, M. and Harris, C. C., Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research, 1994, 54, 4855-4878.
13. 13. Jung, M., Notario, V. and Dritshilo, A., Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Research, 1992, 52, 6390-6393.
14. 14. Yeudall, W. A., Paterson, I. C., Patel, V. and Prime, S., Presence of human papillomavirus sequences in tumour-derived human oral keratinocytes expressing mutant p53. Oral Oncology, European Journal of Cancer, 1995, 31B, 136-143.
15. 15. Field, J. K., Zoumpourlis, V., Spandidos, D. A. and Jones, A. S., p53 expression and mutations in squamous cell carcinoma of the head and neck: expression correlates with the patients' use of tobacco and alcohol. Cancer Detection and Prevention, 1994, 18, 197-208.
16. 16. Ahomadegbe, J. C., Barrois, M., Fogel, S., et al., High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene, 1995, 10, 1217-1227.
17. 17. Nylander, K., Nilsson, P., Mehle, C. and Roos, G., p53 mutations, protein expression and cell proliferation in squamous cell carcinomas of the head and neck. British Journal of Cancer, 1995, 71, 826-830.
18. 18. Brachman, D. G., Graves, D., Vokes, E., et al., Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Research, 1992, 52, 4832-4836.
19. 19. Sakai, E. and Tsuchida, N., Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene, 1992, 7, 927-933.
20. 20. Sakai, E., Rikimaru, K., Ueda, M., et al., The p53 tumor-suppressor gene and rasoncogene mutations in oral squamous-cell carcinoma. International Journal of Cancer, 1992, 52.
21. 21. Lammie, G. A., Fantl, V., Smith, R., et al., D11S287, a putative oncogene on chromosome 11q13 is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene, 1991, 6, 439-444.
22. 22. Buckley, M. F., Sweeney, K. J. E., Hamilton, J. A., et al., Expression and amplification of cyclin genes in human breast cancer. Oncogene, 1993, 8, 2127-2133.
23. 23. Jiang, W., Kahn, S. M., Tomita, N., Zhang, Y. J., Lu, S. H. and Weinstein, I. B., Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Research, 1992, 52, 2980-2983.
24. 24. Tsuruta, H., Sakamoto, H., Onoda, M. and Terada, M., Amplification and overexpression of EXP1 and EXP2/cyclin D1 genes in esophageal carcinomas. Biochemical and Biophysical Research Communications, 1993, 196, 1529-1536.
25. 25. Gorgoulis, V., Zoumpourlis, V., Rassidakis, G., et al., Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. Virchows Archives, 1995, 426, 339-344.
26. 26. Hamelin, R., Fléjou, J-F., Muzeau, F., et al., TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology, 1994, 107, 1012-1018.
27. 27. Roth, J. A., The cell and molecular biology of esophageal carcinoma. Chest Surgery Clinics of North America, 1994, 4, 205-216.
28. 28. Saranath, D., Bhoite, L. T. and Deo, M. G., Molecular lesions in human oral cancer: the Indian scene. Oral Oncology, European Journal of Cancer, 1993, 29B, 107-112.
29. 29. Nees, M., Homann, N., Discher, H., et al., Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Research, 1993, 53, 4189-4196.
30. 30. Wang, L. D., Shi, S. T., Zhou, Q., et al., Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human oesophageal and gastric-cardia carcinogenesis. International Journal of Cancer, 1994, 59, 514-519.
31. 31. El-Deiry, W. S., Tokino, T., Velculescu, V. E., et al., WAF1, a potential mediator of p53 tumor suppression. Cell, 1993, 75, 817-825.
32. 32. Harper, J. W., Adami, G. R., Wei, N., et al., The p21 Cdk-interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 1993, 75, 805-816.
33. 33. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D., p21 is a universal inhibitor of cyclin kinases. Nature, 1993, 366, 701-704.
34. 34. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., et al., A cell cycle regulator potentially involved in genesis of many tumour types. Science, 1994, 264, 436-440.
35. 35. Serrano, M., Hannon, G. J. and Beach, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 1993, 366, 704-707.
36. 36. Toyoshima, H. and Hunter, T., p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell, 1994, 78, 67-74.
37. 37. Cairns, P., Mao, L., Merlo, A., et al., Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science, 1994, 265, 415-416.